Pages that link to "Q38196390"

The following pages link to Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union (Q38196390):

Displaying 18 items.

• Pharmacogenomics in the clinic (Q26782786) (← links)
• Developing precision medicine in a global world (Q26850961) (← links)
• Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations (Q28066738) (← links)
• Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development (Q31017820) (← links)
• Translating RNA sequencing into clinical diagnostics: opportunities and challenges. (Q34519034) (← links)
• Companion diagnostics-a tool to improve pharmacotherapy (Q37583823) (← links)
• Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities (Q38284222) (← links)
• Pharmacogenomic information in drug labels: European Medicines Agency perspective. (Q38364391) (← links)
• Biomarker development in the precision medicine era: lung cancer as a case study. (Q38844239) (← links)
• Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives (Q39456866) (← links)
• What is the future for cancer clinical trials? (Q48639219) (← links)
• Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology (Q49350987) (← links)
• The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics (Q51155348) (← links)
• The evolving potential of companion diagnostics. (Q53064168) (← links)
• Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations (Q57189955) (← links)
• Evolving Japanese regulations on companion diagnostics (Q87236812) (← links)
• Research Choices: Time for Europe to Decide (Q92982818) (← links)
• EU Health Policy, Coherence, Stakeholder Diversity and Their Impact on the EMA (Q92982854) (← links)